Cancer center, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi 030032, China.
Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Chin Med J (Engl). 2023 Aug 20;136(16):1910-1922. doi: 10.1097/CM9.0000000000002768. Epub 2023 Jul 5.
Esophageal cancer (EC) is one of the most common aggressive malignant tumors in the digestive system with a severe epidemiological situation and poor prognosis. The early diagnostic rate of EC is low, and most EC patients are diagnosed at an advanced stage. Multiple multimodality treatments have gradually evolved into the main treatment for advanced EC, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. And the emergence of targeted therapy and immunotherapy has greatly improved the survival of EC patients. This review highlights the latest advances in targeted therapy and immunotherapy for EC, discusses the efficacy and safety of relevant drugs, summarizes related important clinical trials, and tries to provide references for therapeutic strategy of EC.
食管癌（EC）是消化系统中最常见的侵袭性恶性肿瘤之一，具有严峻的流行病学形势和较差的预后。EC 的早期诊断率较低，大多数 EC 患者在晚期被诊断出来。多种多模式治疗已逐渐演变为晚期 EC 的主要治疗方法，包括手术、化疗、放疗、靶向治疗和免疫治疗。靶向治疗和免疫治疗的出现极大地提高了 EC 患者的生存率。本文重点介绍了 EC 靶向治疗和免疫治疗的最新进展，讨论了相关药物的疗效和安全性，总结了相关重要的临床试验，并试图为 EC 的治疗策略提供参考。
